News platforms as important as content, study claims

Share this article:

Health marketing communications firm Enspektos did a deep dive into desktop and media habits and found that who you are in the healthcare industry determines  how much you trust the information that pops up on the screen.

The overall trend was that doctors, nurses and pharmacists overwhelmingly trust information from health websites accessed from desktops more than information obtained via mobile and social network platforms, and they consider news from the Twitterverse to be the least credible. The study found that 78% of polled doctors trusted websites, compared with 69% of nurses and 71% of pharmacists, yet for all three professions, 85% of the polled individuals said they frequently tap the web for medical information.

Mobile content had credibility among 70% of the polled doctors, 46% of the nurses and 61% of the pharmacists, while health information on social networks was considered credible among 10% of the polled docs,  9% of the nurses and 6% of the pharmacists.

The relatively low fondness for social media, however, does not mean that pharma should continue to stay away from the communal space—the report found that these same healthcare providers changed their minds about the integrity of the social-media news flow if they dipped into the social space while doing work-related web surfing or just after scanning websites for related health information.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...